Abstracts tagged "Cell-signalling molecules"

Abstract Number: 0861 • ACR Convergence 2020
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Kevin Thomas¹, Rufei Lu¹, Susan Macwana¹, Joan Merrill¹, Cristina Arriens¹, Eliza Chakravarty¹, Teresa Aberle¹, Holden Maecker², Paul Utz³, Joel Guthridge¹ and Judith James⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, ³Stanford University School of Medicine, Stanford, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…
Abstract Number: 1402 • ACR Convergence 2020
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Kristian Juul-Madsen², John Stegmayr³, Chao Gao⁴, Tue Wenzel Kragstrup¹, Malene Hvid¹, Thomas Vorup-Jensen¹, Richard Cummings⁵, Hakon Leffler³ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark, ³Lund University, Lund, Sweden, ⁴Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center Harvard Medical School, Boston
Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…
Abstract Number: 1526 • ACR Convergence 2020
Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets
Chamutal Gur¹, Postil 158626², Hagit Peleg³, Suhail Aamar³, Fadi Kharouf³, Anat Elazary³, Yolanda Braun-Moscovici Braun-Moscovici⁴, Shuang-Yin Wang⁵ and Ido Amit⁵, ¹Hadassah Medical Center, Hebrew University, Laboratory for Immuno-Genomics, Weizmann Institute of Science, Jerusalem, Israel, ²Rambam Health Care Campus, Technion-Israeli Institute of Technology, Kiriat Mozkin, HaZafon, Israel, ³Hadassah Medical Center, Jerusalem, Israel, ⁴Rambam Health Care Campus, Technion-Israeli Institute of Technology, Haifa, Israel, ⁵Laboratory for Immuno-Genomics, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis, microangiopathy and immune dysregulation. Despite many years of research, the pathogenesis of SSc is poorly understood; there…
Abstract Number: 1952 • ACR Convergence 2020
Activated Memory T Cells Produce Ligands That Cause NF-κB-dependent Inflammatory Activation of the Endothelium: Identification of Novel Therapeutic Targets
Kim Jeucken¹, Jan Piet van Hamburg¹, Lotte Kocken¹ and Sander Tas², ¹Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Utrecht, Netherlands
Background/Purpose: Endothelial cells (EC) are important contributors to inflammation via expression of inflammatory mediators, including cytokines, chemokines and adhesion molecules. Production of these inflammatory mediators…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].